Skip to main content

Table 1 Causes of Death in patients enrolled in the study

From: Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C

  Number of patients
Duration of treatment < 1 year >1 year
Treatment-related mortality - -
Hepatocarcinoma - 1
Hepato-renal syndrome - 1
Esophagic varices bleeding - 1
Heart attack - 1
Percent of enrolled patients death 0% 9%
  1. Note: 2 patients were excluded from the study due to lack of monitoring.